HomeCompareCEO vs MRK

CEO vs MRK: Dividend Comparison 2026

CEO yields 76.85% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CEO wins by $2101752731298.76M in total portfolio value
10 years
CEO
CEO
● Live price
76.85%
Share price
$121.76
Annual div
$93.58
5Y div CAGR
97.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2101752731298.81M
Annual income
$2,095,751,531,332,331,000.00
Full CEO calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CEO vs MRK

📍 CEO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCEOMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CEO + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CEO pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CEO
Annual income on $10K today (after 15% tax)
$6,532.62/yr
After 10yr DRIP, annual income (after tax)
$1,781,388,801,632,481,300.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, CEO beats the other by $1,781,388,801,632,472,800.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CEO + MRK for your $10,000?

CEO: 50%MRK: 50%
100% MRK50/50100% CEO
Portfolio after 10yr
$1050876365649.44M
Annual income
$1,047,875,765,666,170,400.00/yr
Blended yield
99.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CEO
Analyst Ratings
5
Buy
10
Hold
1
Sell
Consensus: Hold
Price Target
$351.00
+188.3% upside vs current
Range: $351.00 — $351.00
Altman Z
2.8
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CEO buys
0
MRK buys
0
No recent congressional trades found for CEO or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCEOMRK
Forward yield76.85%2.76%
Annual dividend / share$93.58$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR97.3%32.7%
Portfolio after 10y$2101752731298.81M$56.8K
Annual income after 10y$2,095,751,531,332,331,000.00$9,798.13
Total dividends collected$2101358184586.15M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$351.00$128.54

Year-by-year: CEO vs MRK ($10,000, DRIP)

YearCEO PortfolioCEO Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$25,863$15,163.37$11,206$366.19+$14.7KCEO
2$99,988$72,314.29$12,650$502.35+$87.3KCEO
3$622,490$515,502.29$14,407$694.19+$608.1KCEO
4$6,583,828$5,917,764.65$16,585$967.82+$6.57MCEO
5$122,455,759$115,411,063.03$19,342$1,363.89+$122.44MCEO
6$4,089,170,455$3,958,142,792.74$22,913$1,947.19+$4089.15MCEO
7$248,095,184,459$243,719,772,071.41$27,662$2,823.89+$248095.16MCEO
8$27,531,195,704,747$27,265,733,857,376.27$34,159$4,173.35+$27531195.67MCEO
9$5,608,598,099,516,063$5,579,139,720,111,983.00$43,337$6,308.80+$5608598099.47MCEO
10$2,101,752,731,298,813,400$2,095,751,531,332,331,000.00$56,776$9,798.13+$2101752731298.76MCEO

CEO vs MRK: Complete Analysis 2026

CEOStock

CNOOC Limited, an investment holding company, explores for, develops, produces, and sells crude oil and natural gas in offshore China, Canada, the United States, the United Kingdom, Nigeria, Argentina, Indonesia, Uganda, Iraq, Brazil, Guyana, Russia, Australia, and internationally. The company operates through three segments: E&P, Trading Business, and Corporate. It produces offshore crude oil and natural gas primarily in Bohai, the Western South China Sea, the Eastern South China Sea, and the East China Sea in offshore China. The company also holds interests in various oil and gas assets in Asia, Africa, North America, South America, Oceania, and Europe. As of December 31, 2019, it had net proved reserves of approximately 5.18 billion barrels of oil equivalent. In addition, the company is involved in the issuance of bonds; sale and marketing of petroleum and natural gas; and surface exploration and sale of coalbed methane. The company was incorporated in 1999 and is based in Central, Hong Kong. CNOOC Limited is a subsidiary of China National Offshore Oil Corporation.

Full CEO Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CEO vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CEO vs SCHDCEO vs JEPICEO vs OCEO vs KOCEO vs MAINCEO vs JNJCEO vs ABBVCEO vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.